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PREFACE
In this era of technical advancement both in medical and surgical fields, there are 
still  cancers  for  which  cure  cannot  be  established  and  only  supportive  care  or 
symptomatic management is possible. Advanced cancers of stomach are apt instances 
for  this.  Though  surgery  and  chemotherapy   are  complimentary  to  each  other  in 
treatment, the acquaintance of knowledge about these malignancies in the cellular level 
paves way for new molecular targets.
A  plethora  of  recently  acquired  information  about  specific  molecular 
abnormalities that "drive" the malignant phenotype, together with profound advances in 
biotechnology, has resulted in the beginning of an era of abundant novel therapeutic 
options to treat patients with a variety of malignant diseases. 
Hence  future  research  directions  should  focus  on  tailoring  therapy  to  specific 
patient  populations,  such  as  those  with  genetic  mutations  on  receptors,  for  optimal 
therapeutic effect. 
Hence this study focuses on the possible role of EGFR in Indian patients 
with gastric malignancy.
INTRODUCTION
Cells are constantly exposed to a variety of external stimuli, ranging from soluble 
endocrine and paracrine factors to signaling molecules on neighboring cells. Thus, it is 
extremely important that the cell correctly interprets these extracellular signals to create 
an appropriate developmental or proliferative response.
Beatson's  original  observation  on  breast  cancer  regression  after  ovariectomy 
published in 1896 provided the first insight into the hormone dependent nature of the 
tumours. In the 1950s Ludwig Gross first showed the clear evidence of tumor specific 
immunogenicity  with  sarcoma  arising  after  exposure  to  methylcholanthrene.  In  1989 
Salmon et al discovered the expression of erb-b2 in breast and ovarian cancer. Since then, 
the discovery of the various receptors and development of corresponding antagonists has 
improved the survival rate of many lethal cancers.
The  identification  of  parameters  that  reflect  biological  behavior  of  individual 
cancer tissues correlating with tumor aggressiveness is a key determinant of prognosis 
and a fundamental issue for the improvement of cancer therapy. Despite recent progress 
in defining the molecular mechanisms of cancer development and tumor progression, 
only a few individual biomarkers providing prognostic information and a therapeutic 
potential  have been identified.  Among them, the EGFR pathways attracted the most 
attention of cancer investigators.[54].
The  epidermal  growth  factor  receptor  (EGFR)  was  the  first  identified  growth 
factor receptor and is implicated in the widest number of human cancers.
In this study we have attempted to identify  the mutant  EGFR in gastric cancer 
patients using Immunohistochemistry methods.
PURPOSE OF STUDY
Worldwide,  Gastric  Cancer  is  the  fourth  most  common  cancer  and  the  second 
leading cause of cancer death (1, 2). In India, Gastric cancer is the most common cancer 
and the most common cause of cancer death. Worldwide esophageal cancer ranks fifth in 
the  mortality  rate  among  tumour  sites  (3).   In  fact,  gastric  and  esophageal  cancers 
together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 
2000-more than lung,  breast,  or  colorectal  cancer  [4].  For  gastric  cancer,  the 5-year 
overall survival rate remains poor, even in comparison with the dismal survival rates 
from the 1970s [5].
The underlying reasons for this disappointingly low survival rate are multifold:
(a) Ineffective screening tools and guidelines; 
(b) Cancer  detection  at  an  advanced  stage,  with  over  50%  of  patients  with 
unresectable disease or distant metastasis at presentation 
(c) High risk for recurrent disease after gastrectomy or   definitive chemotherapy [6]
 (d) Unreliable  noninvasive  tools  to  measure  complete  response  to  Chemotherapy 
[7,8]; and
(e) Limited survival achieved with palliative chemotherapy alone  for patients with 
metastatic or unresectable disease.                   
Over the past decade, the field of drug development has been transformed with 
the identification of and ability to direct treatment at  specific molecular targets.  The 
EGFR monoclonal  antibodies  has  already  been  shown  to  have  promising  results  in 
metastatic breast cancer, head and neck cancer and in lung cancer [31-33].The results 
are  encouraging  from the  colorectal  and  head  and  neck  cancer  trials  for  antibodies 
against EGFR. Active clinical research in esophageal cancer patients towards antibody 
inhibition of EGFR is in their phase I trials.
This  study  focuses  on  the  identification  of  EGFR status  in  gastric  cancers  in 
Indian population.
     
EPIDERMAL GROWTH FACTOR 
             Epidermal growth factor or EGF is a growth factor that plays an important role 
in the regulation of cell growth, proliferation and differentiation. Human EGF is a 6045 
Da protein with 53 amino acid residues and three intramolecular disulfide bonds[22].
EGF  acts  by  binding  with  high  affinity to  epidermal  growth  factor  receptor 
(EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity 
of the receptor. The tyrosine kinase activity in turn initiates a signal transduction cascade 
which results in a variety of biochemical changes within the cell - a rise in intracellular 
calcium levels,  increased  glycolysis and  protein synthesis,  and  expression of certain 
genes including the gene for EGFR , that ultimately lead to  DNA synthesis and cell 
proliferation. The  active  EGFR  is  responsible  for  activating  other  proteins  through 
phosphorylation, with two principal and divergent pathways: the PI3 kinase pathway and 
the MAP kinase pathway. Several further downstream proteins are then activated along 
these  two  pathways.  Additionally,  other  signaling  pathways  can  modulate  proteins 
downstream of EGFR, such as cyclooxygenase-2 (COX-2) and RAS proteins.
EPIDERMAL GROWTH FACTOR
                                      
Three dimensional structure of EGF.
EPIDERMAL GROWTH FACTOR RECEPTOR
EGFR (ERBB1) is a member of the ERBB receptor tyrosine kinase family that 
includes  ERBB2  (HER-2),  ERBB3,  and  ERBB4  [9].  It  consists  of  an  extracellular 
ligand-binding domain, a transmembrane region that anchors the receptor to the plasma 
membrane, and a cytoplasmic region containing a tyrosine kinase domain. The known 
natural  ligands  of  EGFR  include  epithelial  growth  factor  (EGF)  and  transforming 
growth  factor  alpha  (TGF),  which  both  activate  the  receptor  by  binding  to  the 
extracellular  domain  and  inducing  the  formation  of  receptor  homodimers  or 
heterodimers, which is followed rapidly by activation of the receptors’ intrinsic tyrosine 
kinase. In this signal network, ERBB2 is the major partner of EGFR because activated 
heterodimer  complexes  containing  ERBB2  are  more  stable  at  the  cell  surface  than 
complexes containing other EGFR family members [10,11].
Ligand stimulation of EGFR initiates one of the most important cellular growth-
regulatory pathways. As a trans-membrane glycoprotein, the extracellular domain of the 
EGFR is a ligand-binding site for TGF-alpha and EGF ligand cellular mechanisms that 
regulate cell growth [12].
Various  studies  done  on  the  EGFR  status  in  different  organs  has  showed 
encouraging results. This bar diagram depicts the outcome of various studies. Not many 
studies are available in gastric cancer. 
Graph showing the higher and lower percentages of EGFR in different tumor types.
 
The EGFR is constitutively expressed in many normal epithelial tissues, including 
the skin and hair follicle.  Overexpression of EGFR, as wild type or with mutations, 
occurs in many types of human tumors,  including esophageal  (92%), head and neck 
(90%), colorectal (72%), prostate (65%), bladder (65%), ovarian (60%), cervical (60%), 
pancreatic  (89%),  renal  cell  (50%),  and  lung  (50%)  cancers  [13-15].  Expression  of 
EGFR  correlates  with  poor  prognosis  and  advanced  disease.  The  EGFR  signal 
transduction  network  plays  an  important  role  in  various  tumorigenic  processes, 
including  cell-cycle  progression,  angiogenesis,  and  metastasis,  as  well  as  protection 
from apoptosis [9,16].
EGFR SIGNALLING CASCADE
EGFR-MOLECULAR STRUCTURE

EGFR ANTIBODY (CETUXIMAB) 
MOLECULAR STRUCTURE:
FACTORS AFFECTING EGFR SIGNALS
Signals  relayed  through  EGFR receptors  can  be  affected  by  multiple  factors, 
including receptor expression levels and constitutive aberrations to the receptor. Several 
other factors converge to determine the specific quality and magnitude of the signal in 
the ErbB system. These factors include the nature of the system’s ligand, the nature of 
the dimer upon activation by its ligand, dimer degradation rate, and crosstalk with other 
pathways [17].
The EGFR is activated via multiple mechanisms. The EGFR receptor is activated 
by ligands that are derived from within the same cell (autocrine), from neighboring cells 
(paracrine/juxtacrine)  or  as  a  result  of  the  activation  of  heterologous  receptors 
(transactivation). Receptor ligation results in dimerization with other EGFR monomers 
(homodimerization) or with other ErbB receptors (heterodimerization), receptor kinase 
activation and phosphorylation on multiple tyrosyl residues in the C-terminal region. 
These  sites  recruit  phosphotyrosine-binding proteins such as  GRB2 and SHC which 
trigger signaling pathways such as the ERK pathway. Only the ERK activation pathway 
is shown for clarity.
FACTORS AFFECTING EGFR SIGNALS
Abbreviations: 
IGF1-R, insulin-like growth factor-1 receptor; GPCR, G protein-coupled receptor; MMP, matrix metalloproteinase; HB-
EGF, heparin-binding epidermal growth facto
Egfr - Targeted Therapeutics in Development
Several therapies have been developed that specifically target the ErbB receptor 
family.  A  variety  of  strategies  have  been  considered  for  inhibiting  ErbB  receptor 
activity.
• In one strategy, an antibody binds to the receptor, blocking ligand binding and 
the further cascade pathway.
• Accelerating  receptor  internalization  and  degradation  is  another  potential 
target for EGFR. The receptor degradation process effectively "turns off" the 
ErbB response; consequently, it is a valuable target for rational therapy. One 
such  therapeutic  target  is  the  signaling  protein  Cbl,  which  is  important  in 
receptor processing. The Cbl protein attracts ubiquitin-loaded molecules that 
tag the receptor with ubiquitin for recognition and sorting, eventually leading 
to proteosomal digestion [55].
• Another strategy involves the utilization of a low-molecular-weight inhibitor 
of RTK activity, which blocks receptor activation.
• In a fourth strategy, a bispecific antibody binding to a receptor and an immune 
cell facilitates immunologic attack. 
• In  a  fifth  approach,  an  antireceptor  antibody  conjugated  to  molecules  of  a 
cellular toxin or cytotoxic drug promotes receptor internalization and delivery 
of the drug or toxin to the interior of the cell.
• Finally, antisense oligonucleotides complementary to the nucleotide sequence 
of the ligand or receptor block protein translation. 
The magnitude and quality of the downstream response to targeted therapies may 
be determined by a variety of factors that need to be identified in tumors. Thus, another 
important  consideration  in  the  development  of  targeted  therapeutic  agents  is  tumor 
markers; that is, the subcellular determinants of the ErbB inhibitory response, such as 
phosphorylated  (p)-ErbB-1,  p-Erk,  and  p-Akt.  Following  treatment  with  a  particular 
compound,  immunohistochemical  staining  of  receptors,  phosphorylated  aspects  of 
receptors, and ST elements has permitted seimiquantitation of these determinants [46]. 
The  above  discussion  focuses  on  the  current  level  of  knowledge  acquired  in 
EGFR research. Considering the promising outlook we have tried to identify the EGFR 
in our population with gastric cancer.
EGFR PATHWAY AND TARGET SITES
Currently, we have two distinct methods to target EGFR: mAbs to the EGFR and 
small-molecule TKIs. 
HYPOTHESIS
Agents that target the signal transduction pathways are  highly specific for various 
components  of  these  complex  biologic  processes  and  hold  great  promise  for  better 
patient outcomes.
Signaling through ErbB-1 and other family members triggers a powerful network 
of downstream cellular pathways, ending in responses that range from cell division to 
cell death, and from motility to adhesion, and include invasiveness and angiogenesis.
By interfering with cell signaling pathways involved in cell proliferation such as 
inhibition  of  EGFR-associated  tyrosine  kinase  represents  a  novel  approach  to  the 
treatment of solid tumors.
This study addresses the presence of EGFR in cancers of stomach. Since EGFR 
plays a major role in tumor development, angiogenesis and metastasis, targeting these 
receptors may help in the management of these cancers.
REVIEW OF LITERATURE
Many targeted therapies against EGFR for esophageal and stomach cancer are in 
various phase I/II clinical trials which include monoclonal antibodies (mAbs) and signal 
transduction/tyrosine kinase inhibitors (TKIs) for EGFR.
In 1989,Yonemura.y et al conducted a study at Department of Surgery II, School 
of  Medicine,  Kanazawa  University,  Japan  in  242  cancer  stomach  patients  which 
revealed   the presence of EGF receptor in 76(31.4%) patients and the receptor was more 
common  in  diffuse  infiltrating  types,  had  significantly  higher  values  of 
Bromodeoxyuridine labeling indices and associated with a poor prognosis.[18].
In 1993, Demard .F et al found that EGFR levels were higher in tumor samples as 
compared  with  healthy  control  zones.  There  is  no  significant  difference  in  EGFR 
expression according to the various anatomic sites explored or tumoral differentiation 
status. There is a significant difference of distribution for EGFR levels between stages I 
and II tumors and stages III and IV tumors.[19].
In  1995,  Tokunaga  et  al  published  that  EGF  has  been  shown 
Immunohistochemical to be present in 26% of gastric cancers (n = 395).  Fifteen percent 
of gastric cancers (n = 352) were also shown to be positive for both EGF and the EGF 
receptor immunohistochemically, and the simultaneous occurrence of EGF and the EGF 
receptor suggests that  these tumors grow in an autocrine fashion.  Tumors exhibiting 
EGF and the EGF receptor simultaneously show a greater degree of local invasion and 
lymph node metastasis.[47]
In 1995, D’Agnano.I analysed  the expression of EGF-R which revealed that 88% 
of  aneuploid  tumors  were  positive  for  receptor  expression.  On the  contrary,  diploid 
tumors  showed  the  presence  of  EGF-R  only  in  56%  of  cases  (p  =  0.01).  EGF-R 
expression was not related to histological grade. The close relationship between EGF-R 
positive expression aneuploidy,  node involvement,  and tumor invasion suggests that 
these parameters may be indicators of high malignancy. Finally, the results also show 
that aneuploidy and EGF-R-positive expression are indicative of a worse prognosis in 
gastric cancer patients.[52].
In 1996, Kitagawa et al showed that the cumulative survival rate for patients with 
EGFR gene amplification in their primary tumors was significantly lower than that for 
patients without amplification (p < .001). A significant correlation was also observed 
between extensive  lymph node involvement  at  the time of  surgery  and EGFR gene 
amplification  
(p < .05) [35].
In 1999,Senekowitsch-Schmidtke et al in  identified the sufficient uptake of the 
EGFR antibodies  to  the  receptors  and it  can  be  used  for  immunotherapy  and,  after 
labeling with an appropriate radionuclide, called radioimmunotherapy[40].
Garcia j,  Vizoso  et  al  in 2001 found  EGFR levels were significantly higher 
(p<0.0005) in neoplastic tissue than in paired adjacent mucosa samples (median) (n= 84; 
8.7 vs.  3.9 fmol/mg protein).  Intratumoral EGFR levels were significantly correlated 
with tumor stage (p<0.05), and were higher in patients with stage III tumors (median) 
(7.6, 6.4, 12.3 and 7.5 fmol/mg protein for  stages I,  II,  III  and IV, respectively).  In 
addition,  the  tumor/mucosa  ratios  of  the  EGFR  content  were  significantly  higher 
(p<0.05) in patients with stage III tumors (1, 1.8, 3.9, and 0.92, respectively) [24].
In 2002 ,Wang ZH et al published their study showing that the level of expression 
of EGFR was higher in the patients with metastasis and residual gastric cancer(61.11%, 
66%, 66.67%) than in the patients with other cancers, normal gastric mucous membrane, 
atypical hyperplasia(47.83%, 0%, 35%) (P < 0.01) [20].
In 2004 ,Gamboa-Dominguez A et al  evaluated the membrane staining of EGFR 
in  the  neoplastic  cells  and graded  using  a  semiquantitative  score  (0-3+).  Of  the  89 
carcinomas examined, staining of neoplastic cells was weak in 17 (19.1%, score 1+), 
moderate in 16 (18.0%, score 2+), and strong in nine cases (10.1%, score 3+).  EGFR 
reactivity  score  correlated  with  distant  metastases  (P=0.002)  and  clinical  stage 
(P=0.033). EGFR score 0/1+ was significantly associated with an increase in patient 
survival when compared to score 2+/3+ (P=0.0006). In a multivariate analysis, EGFR 
positive cells in muscularis or subserosa (P=0.004), distant metastases (P=0.016) and 
residual disease (P=0.039) were significantly correlated with decreased survival.  EGFR 
reactivity  in  neoplastic  cells  is  an  independent  prognostic  factor  in  gastric 
adenocarcinoma.[53]
Evaluation of PCNA and EGFR status of pretreatment biopsies may identify a 
group of patients likely to derive the greatest benefit from chemoradiotherapy before 
surgery in terms of histologic response and long term survival[21].
In 2003, Ghaderi et al retrospectively investigated in 146 southern Iranian gastric 
cancer patients. Indirect immunostaining was used to evaluate the expression of these 
two receptors in formalin-fixed paraffin-embedded tissue samples. C-ErbB-1 expression 
was observed in 47 (32.2%) and c-erbB-2 expression was observed in 24 (16.4%) of 
tumors.  Significant  positive correlations were observed between c-erbB-1 expression 
and tumor size, local invasion, lymph node involvement and tumor stage. [48]
In 2004, Wilkinson et al in a retrospective review of 38 patients with resected 
gastroesophageal  adenocarcinoma,  demonstrated  that  poorly  differentiated 
adenocarcinomas  of  the esophagus  demonstrated  higher  EGFR expression  than low-
grade tumors based on IHC analysis (57% versus 13%, p = .02). The median overall 
survival times were 35 months for EGFR-negative patients and 16 months for EGFR-
positive patients [39]. Overexpression of EGFR via IHC analysis occurs in 30%-90% 
cancer cases and correlates with poor prognosis [25-30].
In 2004 , Bonner JA et al in his Pre-clinical in vitro and in vivo model systems 
demonstrated radio sensitization with EGFR signaling inhibition addition of cetuximab 
to radiation resulted in a significantly longer median survival time (54 months versus 28 
months, p = .02) and significantly greater 3-year survival rate (57% versus 44%)(36).
In  2004,  Radovich.D  et  al reported  the  phase  II  trial  evaluating  single  agent 
erlotinib in patients with metastatic esophageal cancer regardless of EGFR expression 
who had received up to  one prior  chemotherapy regimen for  metastatic  disease  has 
shown positive response in squamous cell carcinoma. [23].
In 2004, Van Groeningen et al did a multicenter, phase II trial in Japan (n=75) and 
evaluated  the  efficacy,  tolerability,  and  pharmacokinetics  of  gefitinib  in  pretreated 
patients with advanced gastric cancer, showed despite fairly limited antitumor activity, it 
appears that the gefitinib did reach its target, suggesting that tumor control may require 
more than inhibiting EGFR alone.[37-39]
STUDY DETAILS
Type of Study
Prospective descriptive experimental study.
Study Duration
Jan 1, 2005 to December 31, 2005.
Collaborating Institutions
1. Department  of  Surgery,  Government  Royapettah  Hospital,  Kilpauk  Medical 
College, Chennai - 600 010, India.
2. Department  of  Surgical  Gastroenterology,  Government  Royapettah  Hospital, 
Kilpauk Medical College, Chennai - 600 010, India.
3. Division of Immuno Histochemistry, R&D Histopath Lab, Mylapore, Chennai - 600 
004, India.
EXPERIMENTAL DESIGN
Tissue Specimens
Formalin  fixed,  paraffin  embedded,  tissue  from endoscopic  biopsy  of    gastric 
malignancy patients were used for this study. Histological sections were studied by the 
collaborating pathologist at Immuno histochemistry division of the R&D Histopath Lab, 
Mylapore, Chennai - 4.
Technique of Detection
Immunohistochemistry is a multi step process that requires specialized processing of 
the tissue, the selection of appropriate reagents and interpretation of the stained tissue 
sections. In general, Immunohistochemistry staining techniques allow for the visualization 
of antigens, by sequential application of a specific antibody to the antigen, a secondary 
antibody to the primary antibody which serves as a link between the primary antibody and 
streptavidin enzyme conjugate, an enzyme conjugate and a chromogenic substrate. The 
enzymatic activation of the chromogen results in a visible product at the antigen site.
We have used this method in identifying EGF receptor in gastric malignancies, in 
our study.
                                     REAGENTS
MATERIALS AND METHODS
The primary antibody mouse anti-EGRF receptor clone-EGFR-31G7 was obtained 
from  Zymed  Laboratories  Inc,  South  Sanfrancisco,  CA  94080,  USA.  The  necessary 
reagent, buffers and humidifying chambers were utilized from the Immunohistochemistry 
division R&D Histopath Lab; Mylapore, Chennai-4. The primary monoclonal antibody is 
generated in ascitic fluid, protein A purified. The vial is filled to 0.5 ml with reagent 
containing PBS, 1% BSA, and 0.1% sodium azide.
Tissue  section  of  5  microns  cut  with  the help of  Leica microtome.  They  were 
applied to Poly-L-Lysine precoated slides. The following staining protocol was followed. 
Dewaxing done in xylene bath and sections were brought to water through graded alcohol. 
They  were  subjected  to  microwave  antigen  retrieval  in  citrate  buffer  of  pH6  for  30 
minutes.  To  block  non  specific  reactivity  and  staining  from  endogenous  peroxidase, 
sections were incubated with hydrogen peroxide for 5 minutes. 
After rinsing the slides were incubated at room temperature with EGFR  receptor 
primary antibody for 1½ hrs. The slides were washed and biotinylated link was applied and 
incubated for 30 minutes. The sections were incubated in biotinylated streptavidin HRP for 
30 minutes
In between these stages, the slides were rinsed in 10mM phosphate buffered saline. 
DAB, a substrate chromogen was applied and the slides were incubated for 5 minutes. The 
slides  were  thoroughly  rinsed  and  counterstained  with  Mayer's  Hematoxylin  for  30 
seconds and then covered with glycerol jelly and cover slip applied.
Throughout  the  procedure  98  to  100%  humidity  was  maintained  in  a  humid 
chamber. After the above procedure, the slides were ready for screening.
Immunohistochemistry stained positive cells, look brown and negative cells look 
blue. Staining was graded based on the UICC guidelines.
EGFR POSITIVE
EGFR NEGATIVE
STATEMENT OF LIMITATIONS
This study is  based on a  limited number of  patients.  A detailed study of  more 
subjects, in relation to histopathology of cancer and lymph node status and follow up for a 
longer duration will augment the validity of the data.
Downstream of the EGFR pathway are  several  proteins that  may be activated 
without EGFR thus allowing blockade to be overcome. Therefore, while blocking the 
activity of the EGFR protein appears to be a promising anticancer strategy, a simplistic 
strategy of blocking only EGFR is likely to only impact a minority of patients [41].
Epidermal growth factor  receptor  is  overexpressed in a variety of tumor types 
with  variable  frequency  [42].   Of  note,  different  studies  yield  a  wide  range  of 
overexpression  frequencies  in  part  because  of  the  lack  of  consistent  techniques  and 
uniformity for measuring EGFR levels.
The nature of the ligand determines the nature of the dimer formed upon binding; 
this very complex process involves the possibility of multiple ligands and subsequent 
dimer  profiles  that  each  confer  a  particular  mitogenic  response  to  the  cell  [43]. 
Therefore, the magnitude and type of mitogenic response downstream is a contextual 
summation  of  the  individual  effects  of  multiple  ligands  and  receptor  dimerization 
profiles.  Consequently, targeting one specific ErbB subfamily may be insufficient  to 
impart a significant therapeutic benefit [44, 45].  
Trials done on manipulating the EGFR has shown varied results.  Inhibition of 
these  drugs  and  altered  responses  are  due  to  various  factors  which  influence  the 
carcinogenic pathway. Hence modulating the EGFR along with other rate limiting steps 
may be essential.
Molecular diagnostics have been improving everyday. The technique of detection 
based  on  proteomic  molecules,  PCR  and  
western blot methods may yield better results as compared the Immunohistochemical 
staining.
An attempt to quantify the EGFR in normal gastric mucosa will help us to 
understand the validity of this data.
ETHICAL ISSUES INVOLVED
The study was done in tissue obtained from upper gastrointestinal endoscopy. No 
ethical conflicts are involved in this study.
EXCLUSION CRITERION
 Non adenocarcinoma histology of gastric malignancy were excluded from the 
study.
 Patients who were not been able to stratify the differentiation status were not 
included in this study.
 Patients who have had pre biopsy chemotherapy were excluded.
PATIENT CHARACTERISTICS
Total No. of patients
N = 28
Characteristics No. Of patients
1. Gender 
Male     =  20
Female = 8
2. Age 
          Male    = 41 - 83yrs
          Female =           37 - 76yrs
3. Site  
                    Stomach       = 28
4. Histopathology
                  Adenocarcinoma = 28
5. Differentiation
a. Well Differentiated = 13
b. Moderately Differentiated = 7
c. Poorly differentiated = 8
VARIABLES N %
Age group 31-40 1 5.3%
41-50 6 19.7%
 51-60 9 32.1%
 61-70 4 14.3%
 71-80 7 25.0%
 81-90 1 3.6%
Sex Male 20 71.4%
 Female 8 28.6%
Site of biopsy Stomach 28 100%
Differentiation Poor 8 28.6%
 Moderate 7 25.0%
 Well 13 46.4%
STATISTICAL ANALYSIS
Categorical variables sex, histopathology type, site, mitosis and EGFR were given 
in  frequencies  with  percentage.  Continuous  variable  (age)  given  with  mean,  standard 
deviation, minimum and maximum age.
'Epi info 6'  Software is used in this analysis.
Categorical variables associations with positivity were analysed using chi square 
test. Continuous variable associated with positivity were analysed using students ‘t’ test. 
Correlation between age and positivity were analysed using Pearson correlation coefficient 
and graphical representation of the same is given in scattered diagram. The Incidence of 
positivity  was  given  in  proportion  with  95%  confidence  interval.  The  risk  factors 
associated with positivity were analysed using multivariate logistical regression.
OBSERVATIONS
Variables
EGFR status
Negative Positive
n % n %
Age Group 31-40 1 5.3% 0 0
41-50 3 15.8% 3 33.3%
 51-60 6 31.6% 3 33.3%
 61-70 3 15.8% 1 11.1%
 71-80 5 26.3% 2 22.2%
 81-90 1 5.3% 0 0
Sex Male 13 68.4% 7 77.8%
 Female 6 31.6% 2 22.2%
Differentiation Poor 4 21.1% 4 44.4%
 Moderate 5 26.3% 2 22.2%
 Well 10 52.6% 3 33.3%
EGFR Positivity  = 9/28  = 32% ( 16%- 52%) 
The EGFR status in the gastric malignancy studies is 32% that can vary from 16%-52% 
when a confidence interval of 95% is applied.
AGE BASED OBSERVATION
Age
Percentage of staining
0 1- 30% 31- 60% >60% Total Patients
Total
Positivity
31-40 1 0 0 0 1 0
41-50 3 2 0 1 6 2
51-60 6 1 1 1 9 3
61-70 3 0 1 0 4 1
71-80 5 1 1 0 7 2
81-90 1 0 0 0 1 0
Total 19 4 3 2 28 9
Positive  were  more  common  in  the  41-50  and  51-60  age  group.  Definitive 
statistical significance could not be arrived.
AGE DISTRIBUTION
EGFR 
Status N Mean
Standard
Deviation
Student
t-test
Positive 9 58.22 12.143
Negative 19 61.21 13.460
t=0.56
P=0.58
CORRELATIONS
  Grade
age Pearson Correlation -.110
 Sig. (2-tailed) .07
 N 28
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There is poor negative correlation. It means positivity of EGFR is negatively 
correlated with age. The mean age of EGFR positivity is about 3 years less than the 
receptor negative patients.
AGE BASED OBSERVATION
Negative Correlation between Age and Degree of positivity
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This graph represents the analysis of the age based EGFR positivity with the degree 
of  staining.  In  this  study  the  intensity  of  the  receptor  is  negatively  correlated  to  the 
percentage of staining i.e. staining decreases with increasing age of the patient.
SEX BASED EGFR STATUS
Sex
Percentage of staining
0 1- 30% 31- 60% >60% Total Patients
Total
Positivity
Male 13 4 1 2 20 7
Female 6 0 2 0 8 2
Total 19 4 3 2 28 9
χ2=0.26 P =0.61  Not significant
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In this study there is no difference between EGFR positivity and the sex of the patient. 
SEX BASED EGFR STATUS
Sex
Percentage of staining
0 20 30 40 50 60 80
Male 13 1 3 1 0 0 2
Female 6 0 0 0 1 1 0
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The degree of positivity does not correlate with the sex of the patient. 
DIFFERERNTIATION BASED EGFR STATUS
Differentiation 
type
Percentage of staining
0 1- 30% 31- 60% >60% Total Patients
Total
Positivity
Well 
differentiated
10 2 1 0 13 3
Moderately 
differentiated
5 1 1 0 7 2
Poorly 
differentiated
4 1 1 2 8 4
Total 19 4 3 2 28 9
Staining based analysis versus differentiation of tumors did not yield results of 
statistical significance as the analysed patients volumes is less.
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DIFFERENTIATION AND RECEPTOR STATUS
Differentiation type EGFR status Total
Negative Positive
Poorly  differentiated 4 4 8
Moderately differentiated 5 2 7
Well differentiated 10 3 13
Total 19 9 28
χ2=1.07 P =0.42  Not significant
4 4
5
2
10
3
0
2
4
6
8
10
No
. o
f P
at
ie
nt
s
Poor Moderate Well
DIFFERENTIATION  AND POSITIVTY
negative
positive
Positives were more common among poorly differentiated tumors. Staining for 
mutant EGFR were least positive among well differentiated tumors. This correlates well 
with similar studies around the world.
MULTIVARIATE LOGISTIC REGRESSION FOR IDENTIFICATION OF 
RISK FACTORS FOR POSITIVITY
        VARIABLES SIGNIFICANCE ODDS RATIO
1 AGE .097 .987
 2 SEX .888 .868
 3 SITE .879 .000
 4 HPE TYPE .104 .633
COMPARISON WITH INTERNATIONAL STUDIES
STUDY GROUP
NO. OF 
PATIENTS
(n)
EGFR 
POSITIVITY
%
P VALUE
Tokunaga a et al [47] 395 26% -
Wang zh et al [20] 199 66% <0.01
Ghaderi et al[48] 146 32.2% -
He SW et al [51] 104 30.8% <0.05
Gamboa-Dominquez A et al [53] 89 40% <0.033
Suzuki et al [49] 66 51.5% <0.01
Kikkawa et al[50] 65 26.2% <0.05
D'Agnano I[52] 63            56-88% <0.01
Wilkinson et al [34] 38 %57 -
The EGFR positivity in our study is 32%  which range from 16%-52% with a 
confidence  interval  of  95%.  This  is  comparable  to  the  other  studies  done  at  various 
countries.
SUMMARY AND CONCLUSION
Within only a few years,  anticancer therapeutic development against  advanced 
cancers  has  moved  from almost  a  standstill,  with  a  paucity  of  new agents  showing 
potential  for  major  effect,  to  the  rapid  development  of  agents  targeted  against  the 
inherent  basis  of  cancer.  This  transition  is  based  largely  on  the  exponential  rate  of 
information  acquisition  regarding  the  cancer  cell,  particularly  in  terms  of  aberrant 
growth signal transduction and the microenvironment of the cell.
In our study, the presence of EGFR in gastric malignancy was 32% ranging from 
16%-52% with a confidence interval of 95%. This may form the basis for  targeting 
EGFR in carcinoma of stomach.
 The mean age of the patients with EGFR positivity is 3 years less than those 
showing  negative  for  EGFR  receptor.  Similarly  the  degree  for  positivity  is  also 
negatively correlated with age. 
The  sex  of  the  patient,  the  histopathology  of  the  tumor,  the  degree  of 
differentiation is not related to the EGFR status. However the sample studied is small 
and the significance of these factors are to be studied in a larger population.
The correlation between EGFR positivity and the differentiation of tumors is that 
the poorly differentiated tumors express the EGFR more commonly than the moderate 
and  well  differentiated  tumours.  Poorly  differentiated  tumours  staining  positive  for 
EGFR is  almost  50%.Also  the  intensity  of  staining  is  high  in  poorly  differentiated 
tumours.
Although the GI malignancies are a heterogeneous group of malignancies, several 
common  features  make  them  excellent  candidates  for  the  investigation  of  EGFR 
inhibitors such as aggressive tumors with poor prognoses, common overexpression of 
EGFR, and limited treatment option availability. 
Initial studies in a variety of GI malignancies have already shown initial promise 
and one agent, cetuximab, is already approved for use in refractory colorectal cancer. 
While  further  analyses  of  single-agent  EGFR  inhibitors  and  combinations  with 
cytotoxics need to continue, studies that have randomised cohorts will yield definitive 
results. The EGFR protein is just one target in a network of protein-cell signals. In order 
to  best  target  this  network,  we  will  need  to  maximize  our  understanding  of  the 
interactions of all the proteins that affect this network.
Hence,  adequately  designed  clinical  trials  are  necessary  to  ensure  that  the 
usefulness of Signal transduction inhibitors is correctly evaluated and that potentially 
useful agents are not rejected solely on the basis of poor performance in an inadequately 
designed trial with an inappropriate clinical or biologic end point. The full potential of 
these new agents may only be realized with the implementation of radically different 
therapeutic development, evaluation, and treatment paradigms.
There are  literature  evidence stating that  these receptors  may be useful  for  as 
screening tool, as a sensitizer, for assessing the invasiveness, metastatic potential and the 
prognosis of the tumor. However we will be able to draw a firm conclusion from large 
volume studies on Indian population, with long term patients follow up. 
Thus identification of the presence of EGFR status in gastric cancers may help to 
target the tumor cells in addition to the present multimodality management.
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